Literature DB >> 17360756

Small interfering RNAs against the TAR RNA binding protein, TRBP, a Dicer cofactor, inhibit human immunodeficiency virus type 1 long terminal repeat expression and viral production.

Helen S Christensen1, Aïcha Daher, Kaitlin J Soye, Lisa B Frankel, Marina R Alexander, Sébastien Lainé, Sylvie Bannwarth, Chi L Ong, Sean W L Chung, Shahan M Campbell, Damian F J Purcell, Anne Gatignol.   

Abstract

RNA interference (RNAi) is now widely used for gene silencing in mammalian cells. The mechanism uses the RNA-induced silencing complex, in which Dicer, Ago2, and the human immunodeficiency virus type 1 (HIV-1) TAR RNA binding protein (TRBP) are the main components. TRBP is a protein that increases HIV-1 expression and replication by inhibition of the interferon-induced protein kinase PKR and by increasing translation of viral mRNA. After HIV infection, TRBP could restrict the viral RNA through its activity in RNAi or could contribute more to the enhancement of viral replication. To determine which function will be predominant in the virological context, we analyzed whether the inhibition of its expression could enhance or decrease HIV replication. We have generated small interfering RNAs (siRNAs) against TRBP and found that they decrease HIV-1 long terminal repeat (LTR) basal expression 2-fold, and the LTR Tat transactivated level up to 10-fold. In the context of HIV replication, siRNAs against TRBP decrease the expression of viral genes and inhibit viral production up to fivefold. The moderate increase in PKR expression and activation indicates that it contributes partially to viral gene inhibition. The moderate decrease in micro-RNA (miRNA) biogenesis by TRBP siRNAs suggests that in the context of HIV replication, TRBP functions other than RNAi are predominant. In addition, siRNAs against Dicer decrease viral production twofold and impede miRNA biogenesis. These results suggest that, in the context of HIV replication, TRBP contributes mainly to the enhancement of virus production and that Dicer does not mediate HIV restriction by RNAi.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17360756      PMCID: PMC1900231          DOI: 10.1128/JVI.01511-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  80 in total

1.  Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI.

Authors:  K Peden; M Emerman; L Montagnier
Journal:  Virology       Date:  1991-12       Impact factor: 3.616

2.  Dead cell discrimination with 7-amino-actinomycin D in combination with dual color immunofluorescence in single laser flow cytometry.

Authors:  I Schmid; W J Krall; C H Uittenbogaart; J Braun; J V Giorgi
Journal:  Cytometry       Date:  1992

3.  A testis cytoplasmic RNA-binding protein that has the properties of a translational repressor.

Authors:  K Lee; M A Fajardo; R E Braun
Journal:  Mol Cell Biol       Date:  1996-06       Impact factor: 4.272

4.  Constitutive expression of human double-stranded RNA-activated p68 kinase in murine cells mediates phosphorylation of eukaryotic initiation factor 2 and partial resistance to encephalomyocarditis virus growth.

Authors:  E F Meurs; Y Watanabe; S Kadereit; G N Barber; M G Katze; K Chong; B R Williams; A G Hovanessian
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

5.  Relatedness of an RNA-binding motif in human immunodeficiency virus type 1 TAR RNA-binding protein TRBP to human P1/dsI kinase and Drosophila staufen.

Authors:  A Gatignol; C Buckler; K T Jeang
Journal:  Mol Cell Biol       Date:  1993-04       Impact factor: 4.272

6.  An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1.

Authors:  R Collman; J W Balliet; S A Gregory; H Friedman; D L Kolson; N Nathanson; A Srinivasan
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

7.  Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity.

Authors:  D F Purcell; M A Martin
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

8.  Both virus and host components are important for the manifestation of a Nef- phenotype in HIV-1 and HIV-2.

Authors:  M A Ryan-Graham; K W Peden
Journal:  Virology       Date:  1995-10-20       Impact factor: 3.616

9.  Structure of the dsRNA binding domain of E. coli RNase III.

Authors:  A Kharrat; M J Macias; T J Gibson; M Nilges; A Pastore
Journal:  EMBO J       Date:  1995-07-17       Impact factor: 11.598

10.  Human immunodeficiency viruses regulated by alternative trans-activators: genetic evidence for a novel non-transcriptional function of Tat in virion infectivity.

Authors:  L M Huang; A Joshi; R Willey; J Orenstein; K T Jeang
Journal:  EMBO J       Date:  1994-06-15       Impact factor: 11.598

View more
  35 in total

1.  Transcriptional gene silencing of HIV-1 through promoter targeted RNA is highly specific.

Authors:  Kazuo Suzuki; Takaomi Ishida; Makoto Yamagishi; Chantelle Ahlenstiel; Sanjay Swaminathan; Katharine Marks; Daniel Murray; Erin M McCartney; Michael R Beard; Marina Alexander; Damian F J Purcell; David A Cooper; Toshiki Watanabe; Anthony D Kelleher
Journal:  RNA Biol       Date:  2011-11-01       Impact factor: 4.652

2.  HIV-1 RRE RNA acts as an RNA silencing suppressor by competing with TRBP-bound siRNAs.

Authors:  Sylvanne M Daniels; Lucile Sinck; Natalie J Ward; Carlos E Melendez-Peña; Robert J Scarborough; Ibrahim Azar; Elodie Rance; Aïcha Daher; Ka-Ming Pang; John J Rossi; Anne Gatignol
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

3.  Virus meets RNAi. Symposium on antiviral applications of RNA interference.

Authors:  Ronald P van Rij
Journal:  EMBO Rep       Date:  2008-07-18       Impact factor: 8.807

Review 4.  Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs.

Authors:  Mayte Coiras; María Rosa López-Huertas; Mayte Pérez-Olmeda; José Alcamí
Journal:  Nat Rev Microbiol       Date:  2009-11       Impact factor: 60.633

5.  Efficient inhibition of human immunodeficiency virus replication using novel modified microRNA-30a targeting 3'-untranslated region transcripts.

Authors:  Ahmad Nejati; Shohreh Shahmahmoodi; Ehsan Arefian; Zabihollah Shoja; Sayed-Mahdi Marashi; Hamideh Tabatabaie; Yaghoub Mollaei-Kandelous; Masoud Soleimani; Rakhshandeh Nategh
Journal:  Exp Ther Med       Date:  2016-03-02       Impact factor: 2.447

Review 6.  Cell biology of retroviral RNA packaging.

Authors:  Nolwenn Jouvenet; Sébastien Lainé; Lucie Pessel-Vivares; Marylène Mougel
Journal:  RNA Biol       Date:  2011-07-01       Impact factor: 4.652

7.  The cellular TAR RNA binding protein, TRBP, promotes HIV-1 replication primarily by inhibiting the activation of double-stranded RNA-dependent kinase PKR.

Authors:  Viraj R Sanghvi; Laura F Steel
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

8.  ADAR1 interacts with PKR during human immunodeficiency virus infection of lymphocytes and contributes to viral replication.

Authors:  Guerline Clerzius; Jean-François Gélinas; Aïcha Daher; Marion Bonnet; Eliane F Meurs; Anne Gatignol
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

Review 9.  Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies.

Authors:  Laurence Colin; Carine Van Lint
Journal:  Retrovirology       Date:  2009-12-04       Impact factor: 4.602

10.  The A-rich RNA sequences of HIV-1 pol are important for the synthesis of viral cDNA.

Authors:  Cameron P Keating; Melissa K Hill; David J Hawkes; Redmond P Smyth; Catherine Isel; Shu-Yun Le; Ann C Palmenberg; John A Marshall; Roland Marquet; Gary J Nabel; Johnson Mak
Journal:  Nucleic Acids Res       Date:  2008-12-23       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.